Brazil's Medical Cannabis Revolution: 873K Patients and Counting

A Quiet Giant Emerges

While the global cannabis conversation tends to revolve around the United States, Canada, and Western Europe, the most dramatic growth story in medical cannabis may be unfolding in an unexpected place: Brazil.

With more than 873,000 registered medical cannabis patients as of late 2025, Brazil has cemented its position as one of the fastest-growing medical cannabis programs in the world. The country is on track to surpass one million patients by late 2026 or early 2027, a milestone that would make its program larger than most individual U.S. state programs.

The numbers are impressive, but the story behind them — involving regulatory evolution, grassroots patient advocacy, and the emergence of a domestic manufacturing base — reveals a medical cannabis model that offers lessons for markets worldwide.

The Growth Trajectory

Brazil's patient growth has been nothing short of remarkable. The number of registered medical cannabis patients jumped 56 percent from 2023 to 2024, followed by an additional 45 percent year-on-year growth in 2025 versus 2024. In a country of 215 million people, these growth rates suggest that the market is still in its early expansion phase with enormous room to run.

The Kaya consulting firm estimates that the Brazilian medical cannabis market will reach R$1 billion — approximately $187 million — in 2026. Looking further ahead, the projected compound annual growth rate through 2030 is 24.6 percent, which would place the market at approximately R$2.9 billion by the end of the decade.

These projections reflect not just patient growth but the expanding range of products available and the increasing willingness of Brazilian physicians to prescribe cannabis-based treatments for a widening array of conditions.

ANVISA's Regulatory Framework

The regulatory architecture underpinning Brazil's medical cannabis expansion reached a new level of maturity on May 4, 2026, when ANVISA — Brazil's health regulatory agency, equivalent to the FDA — implemented Resolution RDC 1,015/2026.

This comprehensive regulation establishes a permanent, detailed framework for the manufacturing, importation, commercialization, prescription, and dispensation of cannabis-based pharmaceutical products. It replaces the provisional rules that had governed the market and provides the regulatory certainty that businesses and investors need to commit long-term capital.

Key elements of the new framework include standardized quality and safety requirements for cannabis-based products, clear pathways for domestic manufacturing alongside continued importation, defined prescription protocols that give physicians guidance on cannabis-based treatment options, and consumer protection measures that ensure patients receive consistent, tested products.

The significance of RDC 1,015 extends beyond its specific provisions. By establishing a permanent regulatory architecture, ANVISA has signaled that medical cannabis is an accepted and permanent part of Brazil's healthcare landscape — not an experiment that could be reversed at regulatory discretion.

Domestic Manufacturing Begins

One of the most significant developments in Brazil's cannabis market is the emergence of domestic manufacturing capacity.

For years, Brazilian patients relied almost entirely on imported cannabis products — primarily from Canada, the United States, and Europe. Importation created supply chain vulnerabilities, added cost, and limited the range of products available to patients. Customs delays could leave patients without their medication for weeks.

The shift toward domestic production addresses these challenges. ANVISA's expanded rules now allow selected patient associations to cultivate cannabis, creating a legal pathway for Brazilian-grown cannabis to enter the medical supply chain. This represents a fundamental structural change in how the market operates.

Domestic manufacturing also opens the door to product innovation tailored to the Brazilian market. Rather than relying on formulations designed for North American or European consumers, Brazilian manufacturers can develop products optimized for local patient needs, preferences, and medical practices.

Patient Advocacy Drives Change

Brazil's medical cannabis expansion has been driven as much by grassroots patient advocacy as by top-down regulatory initiative. Patient associations — organized groups of medical cannabis users — have been central to pushing for expanded access, and ANVISA's decision to allow certain associations to cultivate cannabis reflects their political influence and organizational capacity.

These associations serve multiple functions: they advocate for policy reform, educate physicians and patients about cannabis-based treatments, provide mutual support for members navigating the medical system, and in some cases now directly participate in the supply chain.

The patient-led model distinguishes Brazil's approach from the more corporate-driven cannabis markets in North America. While commercial interests certainly play a role in Brazil's expanding market, the patient voice has been unusually prominent in shaping policy outcomes.

Conditions and Product Landscape

Brazilian medical cannabis patients use cannabis-based products for a wide range of conditions. The most common qualifying conditions include chronic pain, epilepsy and seizure disorders, multiple sclerosis, anxiety, Parkinson's disease, and cancer-related symptoms.

The product landscape has evolved significantly from the early days of simple CBD oils. Patients now have access to full-spectrum formulations, products with varying THC-to-CBD ratios, capsules, tinctures, and topicals. The recent development of specialized formulations — including Curaleaf's UK-launched suppositories and pessaries, pioneered by international companies that also operate in Brazil — demonstrates the market's growing sophistication.

Research conducted on Brazilian patient populations has contributed to the global understanding of medical cannabis usage patterns. Studies have explored how patients use cannabis products, their treatment motivations, and the outcomes they experience, providing data that benefits medical cannabis programs worldwide.

Implications for Latin America

Brazil's success has implications that extend across Latin America. As the region's largest economy and most populous nation, Brazil's embrace of medical cannabis creates a gravitational pull that influences policy discussions in neighboring countries.

Several Latin American nations are at various stages of developing their own medical cannabis frameworks, and Brazil's experience — both its successes and its challenges — provides a practical reference point. The regulatory model, patient advocacy approach, and market development patterns being established in Brazil may serve as templates for other countries in the region.

The potential for a pan-Latin American medical cannabis market, with cross-border supply chains and regulatory harmonization, remains distant but is increasingly discussed among industry stakeholders and policymakers.

Challenges Ahead

Despite the impressive growth trajectory, Brazil's medical cannabis market faces challenges. Access remains uneven, with patients in wealthier urban areas generally having better access to products and physicians willing to prescribe cannabis treatments. Cost is a barrier for many patients, particularly given Brazil's significant economic inequality.

The regulatory framework, while much improved, still imposes significant compliance burdens that can slow market development. And the cultural stigma around cannabis — while diminishing — has not disappeared entirely, with some physicians remaining reluctant to prescribe cannabis-based products even when clinical evidence supports their use.

A Model Worth Watching

Brazil's medical cannabis journey is far from complete, but its trajectory is unmistakable. From a standing start just a few years ago, the country has built a patient base approaching one million, established a permanent regulatory framework, begun developing domestic manufacturing capacity, and created a market projected to grow at nearly 25 percent annually through the end of the decade.

For international observers, Brazil demonstrates that the medical cannabis model can work outside the North American and European contexts that have dominated the global narrative — including the U.S. DOJ's recent move toward Schedule III rescheduling. For the 873,000-plus patients who now have legal access to cannabis-based treatments, the progress represents something more personal: a healthcare option that many fought hard to secure and that is making a tangible difference in their lives.

If you're researching where medical cannabis is moving next, the easiest place to start is closer to home. Find a dispensary near you on Budpedia — every listing is license-checked, with menus, hours, and reviews to help you compare.